期刊文献+

高血压的基因治疗 被引量:1

暂未订购
导出
出处 《包头医学院学报》 CAS 2005年第3期319-322,F0003,共5页 Journal of Baotou Medical College
  • 相关文献

参考文献16

  • 1Phillips MI. Is gene therapy for hypertension possible [ J ].Hypertension, 1999,33: 8.
  • 2张西蘅.医学分子生物学[M].北京:北京医科大学出版社,1999.973.
  • 3田培坤,任圣俊,任常春,滕青山,曲淑敏,姚明,顾健人.一种新的以细胞表面受体为靶向的基因导入系统[J].中国科学(C辑),1998,28(6):554-560. 被引量:33
  • 4Phillips MI, Wielbo D. Antisens inhibition of hypertension: a new strategy renin - angiotesin Candidate gene [ J ]. Kidney Int,1994,46:1554.
  • 5Wang C,Chao L,Chao J. Direct gene delivery of human tissue Kallikrein reduces blood pressure in spontaneously hypertension rats [ J ]. Clin Invest, 1995,95:1710.
  • 6Chao J, Chao L. Kallikreing gene therapy :a new strategy for hypertensive diseases [J]. Immunopharmacology, 1997,36(2 -3) :229.
  • 7Katsutoshi Y, Cindy W, Lec C, et al. Kallikreing gene delivery attenuate hypertension and enhances renal function in goldblatt hypertensive rats [ J ]. Hypertension, 1998, 31:1104.
  • 8Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery attenuat hypertension, Cardiac hypertrophy and renal injury in salt -sensitive rats[ J]. Hum Gene Ther, 1998,1421.
  • 9王颖,王晋明,张庆华.反义基因疗法——治疗高血压病的新进展[J].高血压杂志,2001,9(1):78-82. 被引量:6
  • 10Wang H, Reaves PY ,Gardon ML. Angiotension Ⅰ - coverting enzyme antisense gene therapy causes permanet antihypertensive effects in the SHR [ J ]. Hypertension, 2000,35(Pt2) :202.

二级参考文献17

  • 1Xu L,Hum Genet Ther,1997年,8卷,467页
  • 2周筱梅,肿瘤,1991年,11卷,242页
  • 3Wu C H,J Biol Chem,1989年,264卷,19685页
  • 4Wu G Y,J Biol Chem,1987年,262卷,4429页
  • 5Pachori A S,Circulation Research,2000年,86卷,11期,1167页
  • 6Wang H,Hypertension,2000年,35卷,Pt 2期,202页
  • 7Tang Xiaoping,Am J Physiol,1999年,277卷,H2392页
  • 8Makino N,Cardiovasc Res,1999年,44卷,3期,543页
  • 9Raizada M,Stamford CT :JAI,1999年,3卷,75页
  • 10Chao J,Hum Gene Ther,1998年,9卷,21页

共引文献37

同被引文献14

  • 1尚希瑶,邵凤民.基因治疗在肾脏疾病中的应用进展[J].医药论坛杂志,2005,26(5):75-77. 被引量:2
  • 2陈莹,田百玲,吴娜,赵冬雪.阿尔茨海默病的病因研究及治疗近况[J].现代医药卫生,2006,22(11):1662-1664. 被引量:6
  • 3张薇,吴娜,赵旭东.阿尔茨海默病及其基因治疗的研究进展[J].中国现代医药杂志,2006,8(7):144-145. 被引量:3
  • 4[4]Bjork lund A,Kirik D,Rosenblad C,et al.Towards aneurop rotective gene therapy for Park in son's disease:use of adenovirus,AAV and lentivrusectors for genetransfer of GDNF to the nro striatalsysteminntherat Park in son ianmodel[J].B rain Res,2000,886:82.
  • 5[8]Tuszynski M H,Smith DE,Roberts J,et al.Targeted in-traparenchymal delivery of human NGF by gentransfer to the primate basalforebrain for 3 months do snotacelerate beta amy-loid plaque deposition[J].Exp N eurol,1998,154:573.
  • 6[11]Davies SW,Turmaine M,Cozens BA.Formation of neuronal intranuclear in clusions underlies the neurological dysfunction in mice transgenic for the HD mutation[J].Cell,1997,90:537-548.
  • 7[12]DiFigliaM,SappE,Chase KO.Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neuritis in brain[J].Science,1997,277:1990-1993.
  • 8[14]Gusella J F,Wexler NS,Lonneally PM.A polymorphic DNA marker enetically linked to Huntington's disease.Nature,1983,306:234-238.
  • 9[15]The Huntington's disease collaborative research group.A novel gene containing a trinueleotide repeat that is expanded and unstable on Huntington's disease chromosomes.Cell,1993.72:971-980.
  • 10[16]David C.Rubinsztein,Jayne Leggo,Rhian coles.Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD)gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats.Am.J.Hum.Genet,1998,59:16-22.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部